Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Who May Qualify: - Patients aged between 18 and 65 years. - Caucasian ethnicity. - Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3). - Have at least one year of history of migraine. - Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody. - Patients able to describe their clinical situation and the characteristics of their headache. - Grant your willing to sign a consent form. Who Should NOT Join This Trial: - Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication. - Neurological focus in the examination. - Pregnancy or breastfeeding period. - Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study. - Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies. - Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug. Always talk to your doctor about whether this trial is right for you.